Pharmaceuticals
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients
Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care for HER2-Negative G/GEJ Adenocarcinoma PRINCETON, N.J. and SUZHOU, China, Oct. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical co...
Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
* This Emergency Use Authorization and CDC recommendation makes Novavax's vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. * Novavax expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid * Fin...
First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial
SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...
DrinkAid Marks Its Third Anniversary with an Exclusive Partnership with Singapore's Top Artistic Talent -- Tobyato, Jaeyelle, and JONT
SINGAPORE, Oct. 3, 2023 /PRNewswire/ -- DrinkAid, Singapore's pioneering health supplement brand that alleviates the side effects of alcohol, marks its third anniversary with an exclusive partnership withSingapore's top artistic talent — Tobyato, Jaeyelle, and JONT. The limited edition boxes, r...
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study
- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment. - Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in...
Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina
EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its$38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility inHigh Point, North Carolina. This expansion doubles the facility's manufacturing capa...
Flat Medical Secures Series C Funding Led by Taiwania Capital, Poised for Global Market Expansion
TAIPEI, Oct. 2, 2023 /PRNewswire/ -- Flat Medical, the leading medtech company specializing in innovative safety solutions for anesthesia, pain medicine, critical care and emergency medicine, is thrilled to announce the successful closing of its Series C funding round. The round was led by renown...
China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally
The documentary outlines China's contribution to vaccine science, research, and production since the COVID-19 pandemic and includes a call for science and infectious disease research to be borderless. BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese R...
MedAlliance Acquired by Cordis for USD 1.135 Billion
GENEVA, Oct. 2, 2023 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has been acquired by Cordis for a 2022 investment of$35M and a 2023 upfront closing payment of$200M, together with regulatory achievement milestones of up to$125M and commercial milestones of up to $775M throu...
Rimegepant is Now Available in Hong Kong, the First Market in Asia, for Migraine Management
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- Pfizer announced the availability of Rimegepant inHong Kong, the first market in Asia, a calcitonin gene-related peptide (CGRP) receptor antagonist for migraine management.[1],[2] There are approximately 12.5% of people living with migraine inHong Kong[3]...
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of ch...
Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better ROCKVILLE, Md. and SUZHOU, China, Sept. 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-qualit...
Jin Medical International Limited Receives NASDAQ Notification Letter Regarding Noncompliance with Continued Listing Rule 5550(a)(3)
CHANGZHOU, China, Sept. 28, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("JinMed" or "the Company") (NASDAQ: ZJYL), aCayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, received a written notification letter ("t...
SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medi...
ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study
SINGAPORE, Sept. 28, 2023 /PRNewswire/ -- ALR Technologies SG Ltd. ("ALRT" or the "Company") (OTCQB: ALRTF), a diabetes management company, announces the patent application titledMethod and System of Monitoring a Diabetes Treatment Plan("Predictive A1c") has been granted in Singapore and has rec...
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (...
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the treatm...
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azaciti...
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and muci...
Week's Top Stories
Most Reposted
BoomerangFX Launches ChatGPT AI Search Advertising for Aesthetic, Wellness and Private-Pay Healthcare Practices, Powered by AUVIA™ AI Clinic Co-Pilot
[Picked up by 1316 media titles]
2026-11-17 23:03Manulife announces Subordinated Debenture issue
[Picked up by 1206 media titles]
2026-11-17 06:45The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1176 media titles]
2026-11-14 13:23Sunbit to Enter Personal Loans in 2027 Along Its Growth Journey: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-18 21:55Cision MCP Brings Consumer Intelligence into Everyday Workflows
[Picked up by 1116 media titles]
2026-11-19 23:00